Oxford BioDynamics (LON:OBD) Announces Earnings Results

Oxford BioDynamics (LON:OBD) issued its earnings results on Tuesday. The biotechnology company reported GBX (0.10) EPS for the quarter, Digital Look Earnings reports. Oxford BioDynamics had a negative net margin of 825.61% and a negative return on equity of 451.74%.

Oxford BioDynamics Stock Up 17.8%

Shares of LON:OBD traded up GBX 0.02 during trading on Friday, reaching GBX 0.11. 18,351,965 shares of the company traded hands, compared to its average volume of 16,501,012. The firm has a market cap of £4.55 million, a P/E ratio of -0.13 and a beta of 0.42. Oxford BioDynamics has a 1-year low of GBX 0.08 and a 1-year high of GBX 0.78. The company has a quick ratio of 2.80, a current ratio of 2.01 and a debt-to-equity ratio of 131.61. The firm has a fifty day simple moving average of GBX 0.18 and a 200 day simple moving average of GBX 0.22.

Oxford BioDynamics Company Profile

Oxford BioDynamics Plc is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.

Its flagship product is EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022.

In March 2021, the Company launched its first commercial prognostic test, EpiSwitch® CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Array Kit.